2329669-72-7

2329669-72-7 structure

Name: Vudalimab
Chemical Name: Vudalimab
CAS Number: 2329669-72-7
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
Create Date: 2022-10-12 10:25:21
Modify Date: 2025-08-25 11:08:09
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation[1].

Name	Vudalimab

Description	Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation[1].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1 Research Areas >> Inflammation/Immunology
In Vitro	XmAb20717 has binding avidity and contributes to T cell activation, including IL-2, CD45+ cells, and IFNγ[1].
In Vivo	XmAb20717 (every two days, for 16 d; NSG mice engrafted with KG1a-luc followed by engraftment with huPBMCs) enhances allogeneic anti-tumor responses in mice[1].
References	[1]. Hedvat M, et, al. Dual Blockade of PD1 and CTLA4 with Bispecific Antibody XmAb20717 Promotes Human T Cell Activation and Proliferation.

No Any Chemical & Physical Properties